4BIO Capital is a London venture firm that builds and backs companies in cell, gene and RNA therapies and other new modalities. It manages two venture funds with $263.6M of gross assets, and began selling interests in a fourth in May 2026. It holds no royalties or revenue interests.

On 11 November 2026 Abbisko told the Hong Kong exchange that Merck KGaA will pay it $20M on the first American sale of PIMJETMI, the drug it licensed to Merck in 2023. The royalty behind the milestone is double-digit, paid from Germany, and in the first half of 2026

Most licences leave the tax with the licensor, and a royalty buyer steps into the licensor's place. The yield on the stream then depends on where the buyer is resident.

On 27 February 2025 the Fifth Circuit let Ovintiv keep more than $608,000 of royalties owed to two family companies in Karnes County, Texas. Ovintiv had misallocated gas flow between September 2016 and January 2018, which meant that it overpaid some royalty owners and underpaid others. Among those overpaid

In January Johnson & Johnson paid a judgment of $0.8B, including interest, to the former stockholders of Auris Health. Their representative had sued in October 2020. The claim rested on a promise in the 2019 merger agreement to use commercially reasonable efforts to win clearance for a surgical robot,

Royalty and profit-share rates published between 1 and 8 November: 12 hard numbers and 15 bands across the window, with word bands converted to ranges. Of the three royalties created, Theriva's from Biossil carries a low single-digit band, capped at USD 250m, and the Boston Scientific

Since 29 September 2026 most imported patented drugs carry a United States duty. Whether the licensor bears part of it depends on a few words in the net sales definition, and in most licences those words point the other way.

California's stem cell agency has committed most of $8.5B of voter-approved bonds as grants. A company that sells a product built on one of them owes the state a royalty of 0.1 per cent of sales for each $1M awarded, for ten years or until it has paid nine times the award.

On 2 and 3 November 2026 Rhythm Pharmaceuticals agreed to pay LG Chem $350M to cut a royalty to 1 percent, signed a $750M term loan led by its revenue interest investor, and loosened the terms of that revenue interest. All three contracts are claims on the same IMCIVREE sales.